Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Arteriogenesis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Arteriogenesis refers to an increase in the diameter of existing arterial vessels.
Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
InactiveUS20030180286A1Improve angiogenesisIncrease vascular permeabilitySenses disorderAntipyreticStress inducedIschemic retinopathy
The present invention relates to the field of pathological angiogenesis and arteriogenesis. in particular, a stress induced phenotype in a transgenic mouse (PIGF- / -) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF-deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumour formation, pulmonary hypertension, vascular leakage (oedema formation) and inflammatory disorders. Molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides. Further, the use of these molecules to treat the latter pathological processes.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Automatic coronary artery calcium detection and labeling system
Method and system for using segmentation and three-dimensional image-processing techniques of a method to create an automatic method to detect coronary artery calcification deposits and identify their location with respect to a major coronary artery. Finally, different scoring algorithms can be applied to generate calcium scores such as Agatston Janovitz, Mass, and Volume. A total score and a more detailed score can be generated based on the major arteries such as right coronary artery, left anterior descending artery, or left circumflex artery to be incorporated into the patient report.
Owner:GENERAL ELECTRIC CO
Pharmaceutical composition for promoting arteriogenesis, and preparation method and applications for the same
InactiveUS20130095060A1Improves post-infarction angiogenesisImproves arteriogenesisNervous disorderPeptide/protein ingredientsPeptideAutologous cell
The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.
Owner:NAT CHENG KUNG UNIV
Method and device for monitoring and improving arteriogenesis
A method for determining an arteriovascular condition of a subject having an arterial blood flow is shown. The method involves determining a temporal progression of an instantaneous blood flow condition of the arterial blood flow as well as deriving a slew rate of the temporal progression during an increase of the temporal progression. In addition, an arteriovascular condition indicator device is shown, which comprises: an input for receiving an input signal representing an instantaneous arterial blood flow condition of a subject and a slew rate monitor connected to the input. A corresponding control device for providing an activation signal is also shown. The control device comprises a maximum detector connected to the slew rate monitor. A method for stimulation of arteriogenesis is also shown, wherein a temporal progression of an instantaneous blood flow condition is monitored, a slew rate of the temporal progression is derived, and the maximum of the slew rate is determined. An external pressure is applied repeatedly to the arteriovascular section in synchronization with the occurrence of the determined maximum.
Owner:BUSCHMANN IVO RAINER +1
Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF− / −) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Stimulation of vascularization with VEGF-B-186
InactiveUS7709450B2Decreased blood flowReduce failurePeptide/protein ingredientsGenetic material ingredientsAngiogenesis growth factorCardiac muscle
VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and / or arteriogenesis, particularly in ischemic mammals, are disclosed.
Owner:FLANDERS INTERUNIV INST FOR BIOTECH +1
Composition and method for modulating vasculogenesis for angiogenesis
InactiveUS20070172423A1Hybrid immunoglobulinsIn-vivo radioactive preparationsLimb ischemiaNucleotide
A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF / VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.
Owner:LI XURI +3
Method to induce neovascular formation and tissue regeneration
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and / or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and / or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.
Owner:FUNDACION UNIVRIA DR RENE G FAVALORO +1
Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
ActiveUS9884012B2Peptide/protein ingredientsMuscular disorderPIGMENT EPITHELIUM-DERIVED FACTORCell biology
A method for promoting muscle or tendon regeneration, and / or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.
Owner:MACKAY MEMORIAL HOSPITAL
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS20130136717A1Increasing concentration and half-lifeGood pharmacological propertiesOrganic active ingredientsHormone peptidesBradykinin receptorCvd risk
The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and / or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and / or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Methods and compositions for improving pial collateral circulation and treating blood clotting disorders
InactiveCN104507468AImprove scoreEasy to primeOrganic active ingredientsFood ingredient functionsTissue inhibitor of metalloproteinasePharmacology
The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
Owner:THE OHIO STATES UNIV
Method to induce neovascular formation and tissue regeneration
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and / or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and / or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.
Owner:FUNDACION UNIVRIA DR RENE G FAVALORO +1
Vessel enlargement by arteriogenic factor delivery
A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge an existing blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.
Owner:ABBOTT CARDIOVASCULAR
Stimulation of Arterial Collateral Growth and Lymphogenesis
InactiveUS20140120106A1Preventing and reducing cellular interactionImprove bioavailabilityBiocidePeptide/protein ingredientsDiseaseLymphatic vessel
Compositions and method for stimulating and controlling arteriogenesis and lymphatic vasculature by preventing and / or reducing the cellular interaction between RAF1 and AKT have been developed. The compositions include molecules that increase the bioavailability of non-phosphorylated RAF1, for example, the RAF1 Ser259 to Ala259 mutant in (RAF1 S259A), and AKT1 inhibitory molecules. Defects, disorders or diseases of insufficient blood or lymphatic vasculature are treated by administering to a patient in need thereof, a pharmaceutical composition comprising a molecule specifically blocking RAF1-AKT crosstalk in a pharmaceutically acceptable carrier or excipient in an amount effective to enhance the growth of blood or lymphatic vasculature in the patient. Compositions can be administered by injection or by controlled or sustained release devices, coating on devices or implants, microparticles, bulking agents or depots, or other techniques providing controlled or sustain release over a period of time effective to induce blood or lymphatic vasculature growth as desired.
Owner:YALE UNIV
Method and system for non-invasive functional assessment of coronary artery stenosis using flow computations in diseased and hypothetical normal anatomical models
A method and system for non-invasive assessment of coronary artery stenosis is disclosed. A patient-specific real anatomical model of a diseased coronary artery of a patient is generated from medical image data of the patient. A hypothetical normal anatomical model is generated for the diseased coronary artery of the patient. Blood flow is simulated in each of the patient-specific real anatomical model of the diseased coronary and the hypothetical normal anatomical model for the diseased coronary artery. A hemodynamic index is calculated using simulated blood flow rates in the patient-specific real anatomical model of the diseased coronary and the hypothetical normal anatomical model for the diseased coronary artery. In particular, fractional flow reserve (FFR) for the diseased coronary artery is calculated as the ratio of the simulated blood flow rate in the patient-specific real anatomical model of the diseased coronary artery and the simulated blood flow rate in the hypothetical normal anatomical model for the diseased coronary artery.
Owner:SIEMENS HEALTHCARE GMBH
Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
ActiveUS9248099B2Effective amountReduce volatilityPowder deliveryGranular deliveryOral medicationNo donors
The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, wherein an NO donor is administered in an intermitting manner to a subject in an amount effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60° C.
Owner:G POHL BOSKAMP GMBH & CO KG
Induction of Arteriogenesis
InactiveUS20140057977A1Prevent diseaseReduce infarct sizeBiocideInorganic active ingredientsNo donorsSurgery
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
Owner:DESMOID
Hypoxia regulated conditionally silenced AAV expressing angiogenic inducers
Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis / arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.
Owner:UNIV OF MIAMI
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS9492495B2Increasing concentration and half-lifeGood pharmacological propertiesHormone peptidesOrganic active ingredientsBradykinin receptorAgonist
The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and / or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and / or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Use of Stabilized Granules Containing Glyceryl Trinitrate for Arteriogenesis
ActiveUS20160271053A1Effective amountReduce volatilityPowder deliveryGranular deliveryOral medicationDiluent
The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, where an NO donor is administered in an intermitting manner to a subject in an amount of effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60° C.
Owner:DESMOID
Induction of arteriogenesis
InactiveUS20160367512A1Effective toolPreventing and treatingInorganic active ingredientsNitro compound active ingredientsNo donorsSurgery
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
Owner:DESMOID
Induction/monitoring of arteriogenesis using sdf1 and pdgfb or inhibition of phd2
InactiveUS20130078224A1Smooth maturationSmooth migrationBiocidePeptide/protein ingredientsPDGFBPerfusion
The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due to the effects of combined PDGFB and SDF-1. The arteriogenic gene profile of the myeloid cells used for therapy can, for instance, be obtained by inhibition of PHD2.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Treatment of Vascular Occlusion by Activation of Notch Signaling
PendingUS20210220434A1Increase blood flowPromote circulationPeptide/protein ingredientsHydroxy compound active ingredientsArterial occlusionsVascular dilatation
Provided are novel treatments for treating various conditions of insufficient blood flow or circulation. The novel inventions disclosed herein are based upon the discovery that increased Notch signaling in arterial vessels has a beneficial effect on blood flow or circulation and tissue regeneration as well as a reduction in tissue damage following arterial occlusion, constriction, or other reduction in blood flow. Increased Notch signaling in arteries promotes beneficial effects, including acute vessel dilation and / or arteriogenesis and collateral arterial growth, and improves recovery following ischemia or other reduced circulation condition. Also provided are medical devices for the delivery of Notch-activating agents to blood vessels.
Owner:RGT UNIV OF CALIFORNIA
Method and device for monitoring and improving arteriogenesis
Owner:ANTEPULS GMBH
Development of novel regulators of angiogenesis
The present invention is directed to novel thalidomide derivative compounds that have activity as angiogenic and arteriogenic compounds. More particularly the compounds have the general structure: (I) wherein R3? is selected from the group consisting oH, C1?-C6? all, C1?-C6? alkenyl, C1?-C6? alkynyl and optionally substituted 5- or 6-membered rings. These compounds can be used to induce angiogenesis or arteriogenesis in a patient in need thereof.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Pathways involved in arteriogenesis and uses thereof
InactiveUS20110002940A1Organic active ingredientsMicrobiological testing/measurementMedicineCell biology
The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in a subject suffering from insufficient arteriogenic capacity. These nucleic acids are among other useful in methods for diagnosing insufficient arteriogenic capacity, treating a subject suffering from insufficient arteriogenic capacity and / or stimulating arteriogenic capacity and / or stimulating arteriogenesis.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
Application of fenofibrate as PPM1D agonist
InactiveCN114377002AIncrease choiceImprove applicabilityOrganic active ingredientsNervous disorderGenes mutationNeutrophil granulocyte
The invention relates to application of fenofibrate as a PPM1D agonist and application of fenofibrate in promoting expression of regulatory gene mutation related to influence on vasoconstriction and arteriogenesis and activation of neutrophile granulocytes, microglia, neurons or endothelium. The invention widens the selection of the existing PPM1D agonist, and has a remarkable application effect in the field of neural immune medicines.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis
InactiveUS20130171163A1Reduce expressionReduced activityOrganic active ingredientsHydrolasesAngiogenesis growth factorTherapeutic angiogenesis
The present invention relates to the regulation of angiogenesis and arteriogenesis by leukocyte antigen-related protein tyrosine phosphatase (LAR). The invention further relates to the use of inhibitors of LAR expression and / or activity to stimulate angiogenesis and / or arteriogenesis.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Methods and Compositions for Improving Pial Collateral Circulation and Treating Blood Clotting Disorders
InactiveUS20150139938A1Improving cerebrovascular collateral circulationReduce riskHeavy metal active ingredientsBiocideTissue inhibitor of metalloproteinasePharmacology
The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
Owner:OHIO STATE INNOVATION FOUND
Use of pedf-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
ActiveUS20160000862A1Well formedPeptide/protein ingredientsMuscular disorderPIGMENT EPITHELIUM-DERIVED FACTORCell biology
A method for promoting muscle or tendon regeneration, and / or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.
Owner:MACKAY MEMORIAL HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com